Loading, please wait ...


News Analytics

.
The decision to temporarily halt enrollment applies only to the PRISM-MDR and PRISM-UDR studies and does neither impact the further development of the murepavadin inhaled program, nor the advancement of the OMPTA program, nor the development of the immuno-oncology candidate, balixafortide (POL6326), which is starting a Phase III trial in combination with eribulin in patients with advanced metastatic breast cancer.

Subject Matter

  • Science and technology 55.93%
  • Healthcare 44.07%
    • Hospitals, doctors and medical care 100.00%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions